Abstract
Metastatic colon cancer (mCC) is a heterogeneous disease, which significantly complicates its prognosis and the choice of an effective treatment strategy for patients. The use of mСС molecular profiling data will allow identifying an optimal approach to justify the choice of therapy and increase the patient’s survival rates.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
